Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

VIR

VIR News

Newswire

16:37

Vir Biotechnology's 10% Owner Sells 191,854 Shares at $5.98/Share.

14:52

Vir Biotechnology's CFO O'Byrne Jason sells 6799 shares at $5.56 on Nov 17.

20:41

Vir Biotechnology's Hepatitis Delta Treatment Shows Promising Results in Phase 2 Trial, Positioning it as a Potential Rival to Gilead Sciences' Bulevirtide.

18:09

Vir Biotechnology Announces Positive Phase 2 Data for Tobevibart & Elebsiran Combination in Chronic Hepatitis Delta Treatment.

15:33

Vir Biotechnology Exec Sells 2,385 Shares at $5.16 per Share on Nov 5.

View More

About VIR

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More